MENU
+Compare
CYCN
Stock ticker: NASDAQ
AS OF
Dec 18 closing price
Price
$2.85
Change
-$0.43 (-13.11%)
Capitalization
8.89M

CYCN Cyclerion Therapeutics Forecast, Technical & Fundamental Analysis

a developer of pharmaceutical products for serious and orphan diseases

Industry Biotechnology
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for CYCN with price predictions
Dec 18, 2024

Momentum Indicator for CYCN turns negative, indicating new downward trend

CYCN saw its Momentum Indicator move below the 0 level on December 18, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 110 similar instances where the indicator turned negative. In of the 110 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for CYCN moved out of overbought territory on December 05, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for CYCN turned negative on December 18, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYCN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CYCN broke above its upper Bollinger Band on December 04, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CYCN entered a downward trend on December 03, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

CYCN moved above its 50-day moving average on December 04, 2024 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CYCN crossed bullishly above the 50-day moving average on December 05, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CYCN advanced for three days, in of 230 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.940) is normal, around the industry mean (14.294). P/E Ratio (0.000) is within average values for comparable stocks, (87.370). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.766). CYCN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (36.630) is also within normal values, averaging (256.769).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CYCN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYCN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CYCN is expected to report earnings to rise 75.00% to -28 cents per share on August 08

Cyclerion Therapeutics CYCN Stock Earnings Reports
Q2'23
Est.
$-0.28
Q1'23
Beat
by $0.14
Q4'22
Beat
by $0.12
Q3'22
Beat
by $5.96
Q2'22
Missed
by $0.01
The last earnings report on May 11 showed earnings per share of -15 cents, beating the estimate of -30 cents. With 613.04K shares outstanding, the current market capitalization sits at 8.89M.
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products for serious and orphan diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
245 First Street
Phone
+1 857 327-8778
Employees
1
Web
https://www.cyclerion.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDECX22.15-0.59
-2.59%
Fidelity Advisor Capital Development C
EKGAX36.62-1.05
-2.79%
Allspring Special Global Small Cap A
IBSAX19.90-0.67
-3.26%
VY® Baron Growth A
FHUMX16.36-0.57
-3.37%
Federated Hermes US SMID Institutional
ETIHX33.22-1.59
-4.57%
Eventide Healthcare & Life Sciences I

CYCN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCN has been loosely correlated with BLUE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCN jumps, then BLUE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCN
1D Price
Change %
CYCN100%
-13.26%
BLUE - CYCN
39%
Loosely correlated
-6.24%
HRTX - CYCN
31%
Poorly correlated
-4.85%
GDTC - CYCN
30%
Poorly correlated
-7.78%
FATE - CYCN
29%
Poorly correlated
-10.37%
FRES - CYCN
28%
Poorly correlated
-6.84%
More